Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Echocardiography 4Electrocardiography 2sulforaphane 1schizandrin 1sacubitril and valsartan sodium hydrate drug combination 1pegfilgrastim 1nicotinamide-beta-riboside 1fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1empagliflozin 1Watchful Waiting 1Vincristine 1Tablets 1Rituximab 1Proton Therapy 1Proteins 1Prednisolone 1Observation 1Medical History Taking 1Lenalidomide 1Laser-Doppler Flowmetry 1Exercise 1Environmental Biomarkers 1Echocardiography, Stress 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Clinical Laboratory Techniques 1Chemoradiotherapy 1Carvedilol 1Blood Pressure Determination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cardiotoxicity × sulforaphane × Clear all
NCT03934905 2024-11-20

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Texas Tech University Health Sciences Center

Phase 1/2 Recruiting
70 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡